Dive Brief:
- Two Phase 3 clinical trials of Sanofi's LixiLan diabetes drug met their targets, the company announced Sunday.
-
The drug is a combination of Sanofi's Lantus and Lyxumia, a drug developed with Zealand Pharma. It is targeted for Type 2 diabetes patients.
-
Type 2 diabetes accounts for more than 90% of all diabetes cases, with the percentage expected to grow.
Dive Insight:
Reuters reports LixiLan sales could reach about $1 billion by 2020, and is the latest in a series of promising diabetes treatments working their way through the development pipeline.
Sanofi presented the results of its trials Sunday at the American Diabetes Association's scientific sessions in New Orleans. The results have been included in submissions to the FDA and the European Medicines Agency, Sanofi said. A FDA decision is expected in August and an EMA decision is expected in Q1 of next year, Sanofi said in a news release.
LixiLan is expected to compete with NovoNordisk's Xultophy, which is expected to face a FDA decision in September. LixiLan already has cleared a FDA advisory committee.